|GRANTWAY
EN

Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies (R21 Clinical Trial Not Allowed)

National Institutes of Health

Share
Favorite
Feedback
Summary
-
05 December 2022
-
-
-
For profit
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
United States of America
Health, Justice and Social Welfare
Overview

The goal of this initiative is to study the role of epigenetic mechanisms regulating HIV CNS (central nervous system) latency and neuropathogenesis in brain derived cells such as macrophages, microglia and astrocytes using novel single cell technologies. Thus this FOA will encourage studies of the role of epigenetic mechanisms regulating HIV CNS latency and neuropathogenesis in brain derived cells such as macrophages and microglia using novel single cell technologies.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
20 April 2023